A Phase II Clinical Study of BBI503 in Adult Patients With Advanced Urologic Malignancies
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 01 Apr 2019
Price : $35 *
At a glance
- Drugs Amcasertib (Primary)
- Indications Carcinoma; Renal cell carcinoma; Urogenital cancer
- Focus Therapeutic Use
- Sponsors Boston Biomedical
- 07 Jul 2017 Status changed from not yet recruiting to withdrawn prior to enrolment due to Low feasibility.
- 13 Sep 2016 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2018.
- 13 Sep 2016 Planned initiation date changed from 1 Jul 2016 to 1 Jan 2017.